Zepatier is owned by Merck Sharp Dohme.
Zepatier contains Elbasvir; Grazoprevir.
Zepatier has a total of 2 drug patents out of which 0 drug patents have expired.
Zepatier was authorised for market use on 28 January, 2016.
Zepatier is available in tablet;oral dosage forms.
Zepatier can be used as treatment of patients infected with hepatitis c virus.
The generics of Zepatier are possible to be released after 04 May, 2031.
|Patent Number||Company||Patent Title||Patent Expiry||Activity Alert|
|These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.|
|US7973040||MERCK SHARP DOHME||Macrocyclic quinoxaline compounds as HCV NS3 protease inhibitors|| |
(6 years from now)
|US8871759||MERCK SHARP DOHME||Inhibitors of hepatitis C virus replication|| |
(8 years from now)
|New Patient Population (NPP)||Dec 9, 2024|
Market Authorisation Date: 28 January, 2016
Treatment: Treatment of patients infected with hepatitis c virus
Click on the highlighted region to filter.
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic